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Conclusion: The use of gated treatment in left breast 
tangential radiotherapy can result in high quantity of 
unrequested CT scans and plans for patients not needing to 
be addressed to this kind of delivery method. Our decision 
tool is able to evaluate patients that will benefit from using 
gating technology without the need to acquire a double CT 
scan and producing a double treatment plan, so making the 
whole workflow easier and faster. 
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Purpose or Objective: The conventional radiotherapy 
technique for breast cancer with locoregional lymph nodes 
consists of half beam tangential fields for the breast, 
junctioning a 3-field AP-PA half beam block for the 
supraclavicular nodes. The AP-PA fields treat a considerable 
volume of healthy tissue to high doses, and the lack of slip 
zone makes it unsuitable for deep inspiration breathhold 
where some variation of breathhold is expected. Full 
volumetric modulated arc would lead to an unwanted low-
dose spread. We therefore investigated the improvements of 
a novel hybrid RapidArc (hRA) technique which is now 
standard in our hospital. 
 
Material and Methods: Previously contoured CT scans from 
10 patients with breast tumors including lococregional lymph 
nodes were used for planning (Eclipse, Varian Medical 
Systems). Prescription was 16 fractions of 2.67 Gy. Clinically 
treated hRA plans consisted of 2 tangential open fields with a 
2 cm cranial slip zone delivering 85% of breast dose and 3 
partial RapidArc arcs of each 80°, delivering the remaining 
dose to the breast and slipzone and full dose to the cranial 
lymph nodes. A range of organs at risk (OAR) constraints 
(from high to low dose) were set on heart, contralateral (CL) 
breast, ipsilateral (IL) and CL lung, esophagus, thyroid and 
ring structures. PTV and OAR dosimetry of hRA plans were 
compared with our old conventional technique hybrid (h)-
IMRT). hIMRT plans consisted of 3 APPA half fields, delivering 
full dose to the cranial lymph nodes, 2 tangential open half 
fields delivering 85% of breast dose and 2 tangential IMRT 
fields delivering the remaining dose to the breast and 
junction. Plans were normalized to deliver similar mean 
dose. PTV and OAR metrics were compared. 
 
Results: Compared to hIMRT, hRA provided better PTV 
coverage and OAR sparing (see Table). V107% of PTV reduced 
from 4.9% to 1.3%. Both the volumes outside the PTV 
receiving 20Gy and 40Gy were reduced significantly by hRA 
(from 2014 to 1440cm3 and from 789 to 312 cm3). hRA spared 
better the esophagus and thyroid gland. Mean lung dose and 
IL lung receiving 20Gy reduced significantly, at the expense 
of a non-significant 5% increase of V5Gy to the IL lung. 
 
 
 
Conclusion: The novel hRA technique had dosimetric 
advantages for almost all investigated OAR. hRA spared 
significantly the healthy tissue around the supraclavicular 
lymph nodes. The 2cm slip zone in the hRA plan, which is not 
possible to create when using junctioning half beams, makes 
this technique also suitable for breathhold treatment. 
 
Poster Viewing: 2: Clinical: Health economics, urology and 
brain  
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Purpose or Objective: Radiotherapy centres have the 
complex task to simultaneously improve patient outcomes 
(survival and toxicity), safety, service (such as shared 
decision making) and efficiency. To address this multi headed 
challenge, centres are forced to innovate. The objective of 
our study is to investigate how well Dutch Radiotherapy 
centres have implemented innovation within the care 
environment. Our two research questions are: 1. What is the 
annual number of treatment -, technological - and 
organisational innovations? And 2. Are there differences 
between the centres?  
 
Material and Methods: A descriptive cross-sectional study 
was conducted. Two investigators started with semi 
structured interviews in participating centres, generally with 
the head of physics and the head of the department. 
Innovations in the annual policy plans from 2011- 2013 (3 
years) were classified into 3 distinct categories based on 
literature: new or significantly improved 1) treatment, 2) 
technology, or 3) organisational processes, implemented in 
clinical routine. Incremental improvements to existing 
treatments, technologies, or organisational processes were 
not included in the results below. Centres without annual 
policy plans were asked to create their own inventory, or to 
tick listed innovations from other centres. Finally, all 
participating centres received the listed innovations from 
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other centres with the request to check if their own 
inventory was complete. The classification was checked 
independently by two senior investigators. 
 
Results: Out of the 20 centres invited to participate in the 
study 15 took part in the final study, 8 of which were 
academic and 7 non-academic.As shown in the table below, 
the number of innovations in academic centres was higher 
but not significantly different from non-academic centres. An 
academic centre implemented on average 17 (range 12-27) 
innovations per year and a non-academic centre on average 
of 14 (range 10-18). Treatment innovation (e.g. breath hold 
mamma, IGRT) was the most frequently implemented 
innovation (n=102) followed by organisational innovation 
(e.g. starting a satellite, new Electronic Patient 
Record)(n=71) and technological innovation (e.g. IMRT, 
technological new linacs)(n=61). In each innovation category 
an academic centre is performing the highest number of 
innovations. 
 
 
 
Conclusion: Radiotherapy centres in the Netherlands 
implement on average 16 innovations per year in their 
department; this number is not significantly different for 
academic or non-academic centres. These numbers confirm 
that radiotherapy is a very dynamic and innovative discipline. 
In our next study we will investigate what are the key drivers 
for innovation.  
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Purpose or Objective: The efficiency in the translation of 
scientific discoveries into clinical practices in general 
healthcare is low. Previous research concluded that 
approximately 5 % of peer–reviewed papers concern findings 
which are routinely implemented. We hypothesize that 
implementation rates in radiotherapy will be higher, in 
particular in an institution which has an integrated strategy 
for research, valorisation and patient care, and has a data 
centre for clinical trials including a software development 
team.Our aim is to study the efficiency of research 
implementation in the clinic either in routine or in clinical 
trials in a large radiotherapy institution over a period of 4 
years. The research questions are two-fold: 1) what is the 
percentage of published findings routinely implemented in 
clinical practice? And 2) what is the rate of clinical testing of 
laboratory and technological published findings? 
Furthermore, we have tried to identify the facilitators and 
barriers within this process. 
 
Material and Methods: The scientific publications of 
researchers of our own institute were listed for the period 
from 2008-2011 (4 years), categorized as shown in the table 
below. From the literature we listed the facilitators and 
barriers in the implementation process. We asked clinicians 
of the tumour expert groups if the published study had yet 
been implemented into clinical practice or clinical trials, and 
which facilitators or barriers were applicable. This has been 
verified by an independent investigator. We calculated 
implementation rates and the frequency of mentioned 
facilitators and barriers. Furthermore the head of research 
scored whether pre-clinical and technological scientific 
publications had been tested in clinical trials. This was 
checked independently by two senior investigators.  
 
Results: Internal researchers published 244 papers of which 
79 (32%) were clinical (technological) papers. In total, 45/244 
papers (18%) were routinely implemented; of the 79 clinical 
(technological) papers, this percentage was even higher: 33% 
(26/79). Overall 73/244 (30%) papers (all technical or 
laboratory papers ) were tested in a clinical environment, 
mostly in the context of a research project (Table).The main 
facilitator was level of evidence, and the main barriers were 
workload and high complexity (Figure).  
 
 
 
 
Conclusion: The efficiency in translation of published 
research in radiotherapy in reaching the clinic was much 
higher than in general healthcare. Level of evidence was an 
important facilitator, whereas high workload and complexity 
were important barriers. The next step will be to look at the 
time needed for implementation and to investigate 
implementation rate in other centres. We propose that the 
rate of clinical implementation of published research 
findings, routinely or in trials, should be a quality indicator of 
integrated research-patient care organisation such as a 
comprehensive cancer centre.  
 
 
